Guselkumab for the treatment of palmoplantar pustulosis.

Published in: Expert opinion on biological therapy (2020)

The first double-blinded randomized placebo-controlled trial (RCT) of guselkumab for PPP has been completed. The drug was effective, and guselkumab could be used as a new agent for PPP treatment, in addition to several conventional therapeutics. However, several issues remain. For example, there is no mouse model of PPP, so careful observation of human PPP patients and establishment of a good experimental PPP model are essential.

Keyphrases

mouse model
end stage renal disease
double blind
endothelial cells
newly diagnosed
chronic kidney disease
emergency department
small molecule
clinical trial
randomized controlled trial
open label
replacement therapy
phase ii
induced pluripotent stem cells